Date: 2024-12-21 Page is: DBtxt003.php txt00004741 | |||||||||
Peter Burgess Dialog | |||||||||
Burgess COMMENTARY | |||||||||
Peter Burgess
Dear Chris
You have identified a big issue ... but this big issue has been around for
a very long time, and bog pharma has no intention of it ending any time
soon.
You pose a number of good questions.
1) Should health care remain at the mercy of commercial imperatives?
2) Should some form of price or profit regulation be applied in spite of
the macro-economic free market principles in effect? Ironically big pharma
conveniently resists these when it comes down to free and fair competition
and negotiation.
3) How can transparency in medicines pricing effectively be promoted or
enforced so that real costs of development & promotion are revealed?
4) How can a moral/ethical perspective be brought into play in
pharmaceutical markets? Carrots and/or sticks?
5) How can introduction of single-payer social health insurance programmes
be expedited?
You are asking questions about a very big issue. In my view there is a huge
systemic problem that has been exploited for a very long time by investors
and C-level executives ... a problem that business schools should have
addressed but rather have chose to look the other way and go in another
direction.
It is the conventional wisdom that big profits are needed to incentivize
effective research and development, and therefore produced healthcare
progress. My observations of business practice over many years suggests
that this motivates investors, but does rather little for the scientists
who actually do the work of research. The system has been hijacked by
people who spin messages and distribute misinformation.
I think there will be a major change in the way society functions in the
relatively near future. There is the possibility to use the ubiquitous
mobile data platform (cell phone) to aggregate important data as well as
merely socially interesting (but actually irrelevant) data. The 'rip-off'
that is the norm in so many commercial activities will start to be get some
push-back from society ... from potential customers. This will change
commercial behavior. This will change political behavior. The power of
lobbyists at the moment is at a historic high, but that is starting to
change as elected officials start to get heat from ordinary people who are
increasingly engaged with data that highlights commercial profit at the
expense of social good.
My own effort in this space is something I call TrueValueMetrics. TVM is
value accounting that not only takes into account the money flows that
produce profit, but the value flows that are important for society ... the
so called externalities. TVM is based on traditional accounting concepts
but addresses the performance of both the organization and the place
(community) where the economic activity takes place. At the moment all the
value chains are optimized for the commercial investor ... under TVM the
value chains can be more easily optimized for social impact. This is
important as the new field of social investing becomes more commonplace ...
something that needs to happen if the major issues on the planet are to get
addressed in a meaningful way.
Peter Burgess
|